Skip to main content
NanoRepro AG logo

NanoRepro AG — Investor Relations & Filings

Ticker · NN6 ISIN · DE0006577109 LEI · 3912008FCA63AGIMEV74 F Manufacturing
Open in API
Filings indexed 412 across all filing types
Latest filing 2025-07-18 Earnings Release
Country DE Germany
Listing F NN6

About NanoRepro AG

https://www.nanorepro.com/en/

NanoRepro AG is a company specializing in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The products are designed for both home and professional use. The company's portfolio covers various health areas, including family planning, preventive healthcare, disease detection, food intolerances, allergies, and infectious diseases. The primary goal is to provide accuracy in self-diagnostics for rapid disease detection and health monitoring.

Recent filings

Filing Released Lang Actions
NanoRepro AG: Endgultige Jahreszahlen 2024 - NanoRepro bleibt auf Wachstumskurs
Earnings Release Classification · 100% confidence The document is titled "NanoRepro AG: Endgültige Jahreszahlen 2024 – NanoRepro bleibt auf Wachstumskurs" (Final Annual Figures 2024). It contains detailed financial metrics for the past fiscal year (2024), including revenue, gross profit, net loss reduction, and outlook for 2025 and 2026. The content clearly summarizes the full-year financial performance and strategic updates, which aligns with the description of an Earnings Release (ER) or potentially an Interim/Annual Report summary. However, since it explicitly states "Endgültige Jahreszahlen 2024" (Final Annual Figures 2024) and provides key performance indicators (KPIs) and management commentary on the full year, it functions as the primary announcement of the annual results. Given the options, this is best classified as an Earnings Release (ER) which typically announces the key figures of the period, or potentially a summary preceding a full 10-K filing. Since it is a formal announcement of the final annual figures released on July 18, 2025, covering the 2024 fiscal year, and is structured like a press release announcing results, ER is the most appropriate fit among the choices for a results announcement that is not the full 10-K document itself. The document length (10,882 chars) is substantial but it is presented as a news release distributed via EQS, suggesting it is the initial formal release of the annual results, fitting the ER definition better than the comprehensive 10-K. FY 2024
2025-07-18 German
NanoRepro AG: Dr. Olaf Stiller, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains sections detailing 'Angaben zu den Personen, die Führungsaufgaben wahrnehmen' (Information on persons discharging managerial responsibilities) and 'Art des Geschäfts: Kauf' (Type of transaction: Purchase). This directly corresponds to the definition of Director's Dealing reports, which track personal share transactions by executives and directors. The appropriate code is DIRS.
2025-05-26 German
NanoRepro AG: Dr. Olaf Stiller, buy
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains sections detailing 'Angaben zu den Personen, die Führungsaufgaben wahrnehmen' (Information on persons discharging managerial responsibilities) and 'Angaben zum Geschäft/zu den Geschäften' (Information on the transaction), specifically noting a 'Kauf' (Purchase) of shares by Dr. Olaf Stiller, who holds the position of 'Aufsichtsrat' (Supervisory Board member). This content directly matches the definition for Director's Dealing reports.
2025-05-19 German
NanoRepro AG: Dr. Olaf Stiller, buy
Director's Dealing Classification · 100% confidence The document is titled 'Directors’ Dealings' and contains a section explicitly stating 'Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen' (Notification and public disclosure of transactions by persons discharging managerial responsibilities and by persons closely associated with them). It details a 'Kauf' (Purchase) transaction by Dr. Olaf Stiller, who holds the position of 'Aufsichtsrat' (Supervisory Board member) in NanoRepro AG. This content directly matches the definition for Director's Dealing reports.
2025-05-08 German
NanoRepro AG: NanoRepro AG investiert in Kaltplasma-Technologie und baut ihre Marktstellung im Gesundheits- und Lifestyle-Sektor aus
M&A Activity Classification · 99% confidence The document is a corporate announcement dated April 29, 2025, detailing a strategic investment by NanoRepro AG in a startup focused on cold plasma technology ('hyped about science' GmbH). It discusses a 33% participation, technology integration, market analysis for related products, and future operational restructuring. This type of announcement, focusing on corporate actions like investments, acquisitions, or significant strategic shifts, is typically classified as a general regulatory filing or a specific corporate action announcement. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a management discussion (MDA), nor a proxy/dividend notice, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a material corporate event announcement distributed via a news service (EQS News). It is not a Report Publication Announcement (RPA) because it is the substance of the news, not just an announcement that a report is available.
2025-04-29 German
NanoRepro AG: NanoRepro erhalt EU-Qualitatsmanagementbescheinigung nach Verordnung (EU) 2017/746 fur In-vitro-Diagnostika
Regulatory Filings Classification · 100% confidence The document is a news release dated April 16, 2025, announcing that NanoRepro AG received an EU Quality Management Certificate according to Regulation (EU) 2017/746 (IVDR) for its In-vitro Diagnostics. This is a specific regulatory compliance update concerning product quality systems, not a full financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement about regulatory compliance and certification. Since there is no specific category for 'Regulatory Compliance Update' or 'Certification Announcement', and it is a formal announcement distributed via EQS News, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory news that doesn't fit the other specific codes. The document length (6153 chars) is substantial enough that it is the primary announcement itself, not just a brief notice pointing to an attached report (which would suggest RPA).
2025-04-16 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.